Outbreak response choice | Number of iterations that require > 100 million doses | Number of iterations that require > 500 million doses | Number of iterations with expected mOPV stockout | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
mOPV1 | mOPV2 | mOPV3 | tOPV | IPV | mOPV1 | mOPV2 | mOPV3 | tOPV | IPV | mOPV1 | mOPV2 | mOPV3 | Any | |
Base case | 23 | 12 | 8 | N/A | 6 | 1 | 0 | 1 | N/A | 2 | 19 | 11 | 7 | 27 |
Duration of mOPV use after homotypic OPV cessation (years) | ||||||||||||||
- 3 | 20 | 11 | 7 | N/A | 17 | 0 | 0 | 1 | N/A | 11 | 18 | 11 | 7 | 27 |
- through Tend | 24 | 12 | 9 | N/A | 1 | 0 | 1 | 1 | N/A | 0 | 19 | 11 | 8 | 28 |
Minimum R0 to trigger block-wide response | ||||||||||||||
- 8 | 32 | 18 | 14 | N/A | 8 | 2 | 0 | 1 | N/A | 3 | 28 | 16 | 13 | 44 |
- 13 | 20 | 11 | 11 | N/A | 6 | 2 | 0 | 1 | N/A | 3 | 17 | 9 | 11 | 30 |
Response delay (days)a | ||||||||||||||
- Always 30 | 22 | 13 | 8 | N/A | 5 | 1 | 0 | 0 | N/A | 2 | 18 | 11 | 7 | 26 |
- Always 45 | 23 | 12 | 8 | N/A | 6 | 1 | 0 | 1 | N/A | 3 | 19 | 11 | 7 | 27 |
- Always 60 | 24 | 12 | 8 | N/A | 8 | 2 | 0 | 1 | N/A | 5 | 20 | 11 | 7 | 28 |
oSIA vaccine between OPV2 and OPV13 cessation for serotype 2 outbreaks | ||||||||||||||
- tOPV | 23 | 0 | 8 | 11 | 6 | 1 | 0 | 1 | 0 | 2 | N/A | N/A | N/A | N/A |
- IPV | 23 | 12 | 8 | N/A | 21 | 1 | 0 | 1 | N/A | 3 | N/A | N/A | N/A | N/A |